期刊文献+

福建地区汉族人群骨保护素基因rs2073617T/C多态性与急性冠脉综合征病变程度的关系 被引量:1

Correlation between osteoprotegerin gene rs2073617T/C polymorphism and severity of acute coronary syndromes in Fujian area
下载PDF
导出
摘要 目的探讨福建地区骨保护素(osteoprotegerin,OPG)基因启动子rs2073617T/C位点基因多态性与急性冠脉综合征(acute coronary syndrome,ACS)病变程度的关系。方法采用多聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)技术检测360例ACS患者和120例正常对照者OPG基因rs2073617T/C多态性位点基因型,同时采用DNA测序对酶切产物进行鉴定,并比较其与ACS及其病变枝数和冠状动脉积分的关系。结果 OPG基因rs2073617T/C多态性TC、TT、CC三种基因型在ACS组和对照组中的频率分别为43.3%、33.3%和23.3%,以及47.7%、26.7%和25.6%;两组比较差异无统计学意义(P>0.05);ACS患者冠状动脉单枝、双枝、多枝病变组间OPG基因rs2073617T/C基因型频率差异无统计学意义(P均>0.05)。结论 OPG基因rs2073617T/C多态性与福建地区汉族人群中ACS的发生及冠状动脉病变程度无相关性。 Objective To detect the association of osteoprotegerin gene rs2073617T/C polymorphisms with severity of acute coronary syndrome(ACS) in Fujian area.Methods The polymerase chain reaction restriction fragment length polymorphism(PCR-RFLP) was used to detect OPG gene rs2073617T/C in three hundred and sixty patients with ACS(cases group) and 120 matched control group.DNA sequences of enzyme digested products were also analyzed.Results The frequencies of TC,TT and CC types of OPG rs2073617T/C polymorphism in ACS patients and controls were 43.3%,33.3% and 23.3% VS 47.7%,26.7% and 25.6%.There was no significant difference in the distribution frequency of three genotypes and two alleles of OPG rs2073617T/C between the ACS and control groups(P〉0.05).OPG gene rs2073617T/C in all lesions was no difference among the groups(P〉0.05).Conclusion OPG gene polymorphism was existing in Hans population of Fujian Han,and have no association with acute coronary syndrome and severity of ACS in Han nationality of Fujian.
出处 《东南国防医药》 2011年第5期385-388,共4页 Military Medical Journal of Southeast China
基金 南京军区医学科技创新项目资助(09MA094)
关键词 骨保护素 急性冠脉综合征 多态性 DNA测序 osteoprotegerin acute coronary syndrome gene polymorphism DNA sequences
  • 相关文献

参考文献10

  • 1罗助荣.骨保护素系统与动脉粥样硬化的研究进展[J].东南国防医药,2010,12(6):523-525. 被引量:3
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2146
  • 3Antman EM,Armstrong PW,Bates ER,et al.2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction[J].JACC,2008,51 (2):210-247.
  • 4Sirnonet WS,Laeey DL,Dunstan CR,et al.Osteoprotegerin:a novel seelated protein involved in the regulation of bone density[J].Cell,1997,89(2):309-319.
  • 5Tsuda E,Goto M,IVlochizuki S,et al.Isolation of a novel cytokinefrom hurmn fibroblasts that specifically inhibits osteeclastogenesis[J].Bioehem Biophys Res Contain,1997,234 (1):137-142.
  • 6Palazzuoli A,Ascione R,GallottaM,et al.Osteoprotegerin and Btype natriuretic peptide in acute coronary syndromes with preserved systolic function:relationto coronary artery disease extension[J].Int J Cardiol,2009,137 (3):295-298.
  • 7Omland T,Ueland T,Jansson AM,et al.Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes[J].J Am Coll Cardiol,2008,51 (3):627-633.
  • 8Hofbauer LC,Schoppet M.Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease[J].JACC,2002,87(9):4078-4079.
  • 9Ohmori R,Momiyama Y,Taniguehi H,et al.Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men[J].Atherosclerosis,2006,187 (1):215-217.
  • 10Soufi M,Schoppet M,Sattler AM,et al.Osteoprotegerin gene polymorphisms in men with coronary artery disease[J].Clin Endocrinol Metab,2004,89 (8):3764-3768.

二级参考文献49

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J].Cell,1997,89(7):309-319.
  • 3Sato K,Niessner A,Kopecky SL,et al.TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atheroselerotic plaque[J].J Exp Med 2006,203(3):239-250.
  • 4Bennett BJ,Seatena M,Elizabeth A,et al.Osteorotegerin inaetivation accelerates advanced atherselemtic lesion progression and cadcifieation in older apoE-/-Mice[J].Arterioseler Thromb Vasc Biol,2006,26(9):2114-2117.
  • 5Ovchinnikova O,Gylfe A,Bailey L.et al.Osteopmtegerin promotes fibrous cap formation in atheresclemtic lesions of APOE-deftcient mice-brief report[J].Arterioscler Thromb Vasc Biol,2009,29(10):1478-80.
  • 6Jono S,Ikari Y.Shioi A,et al.Serum osteopmtegerin levels are associated with the presence and severity of coronary artery disease[J].Circulation,2002.106(11):1192-1194.
  • 7Helske S,Kovanen PT,Lindstedt KA,et al.Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload[J].Eur J Heart Fail,2007,9(5):357-363.
  • 8Ohmori R,Momiyama Y,Taniguchi H,et al.Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men[J].Atherosclerosis,2006,187(2):215-217.
  • 9Crisafulli A,Micari A,Altavilla D,et al.Serum levels of osteoprotegerin and RANKL in patients with ST-elevation acute myocardial infarction[J].Clin Set(Lond).2005,109(4):389-395.
  • 10Omland T,Drazener MH,Ueland T,et al.Plasma osteoprotegenfin levels in the general populationg:relation to indices of left ventficular structure and function[J].Hypertension,2007,49(6):1392-1398.

共引文献2147

同被引文献13

  • 1谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013:169.
  • 2Li R,Zhang Q,Yang D,et al.Prevalence of polycysticovary syndrome in women in China:a large community-based study[J].Hum Reprod,2013,28(9):2562-2569.
  • 3Moran LJ,Misso ML,Wild RA,et al.Impaired glucose tolerance,type 2 diabetes and metabolic syndrome in polycystic ovary syndrome:a systematic review and meta-analysis[J].Hum Reprod Update,2010,16(4):347-363.
  • 4Boomsma CM,Eijkemans MJ,Hughes EG,et al.A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome[J].Hum Reprod Update,2006,12(6):673-683.
  • 5Haoula Z,Salman M,Atiomo W.Evaluating the association between endometrial cancer and polycystic ovary syndrome[J].Hum Reprod,2012,27(5):1327-1331.
  • 6Rizzo M,Berneis K,Spinas G,et al.Long-term consequences of polycystic ovary syndrome on cardiovascular risk[J].Fertil Steril,2009,91(4 Suppl):1563-1567.
  • 7Rotterdam.ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS)[J].Fertil Steril,2004,81(1):19-25.
  • 8Grigorova M,Punab M,Ausmees K,et al.FSHΒ promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men[J].Hum Reprod,2008,23(9):2160-2166.
  • 9Schüring AN,Busch AS,Bogdanova N,et al.Effects of the FSH-β-subunit promoter polymorphism 211G→T on the hypothalamic-pituitary-ovarian axis in normally cycling women indicate a gender-specific regulation of gonadotropin secretion[J].J Clin Endocrinol Metab,2013,98(1):E82-E86.
  • 10La Marca A,Papaleo E,Alviggi C,et al.The combination of genetic variants of the FSHΒ and FSHR genes affects serum FSH in women of reproductive age[J].Hum Reprod det,2013,28(5):1369-1374.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部